Skip to main content

Table 1 Patient, tumor, and treatment characteristics

From: Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors

Parameter

Cohort (n = 70)

Patients-no.

70

Tumors (targets)-no.

76

Follow-up time-median (range)

15 (8–22) months

Median age-median (range)

74 (54–91) years

Sex

 

 M-no. (%)

28 (40.0)

 F-no. (%)

42 (60.0)

Location

 

 Right upper lobe-no. (%)

18 (23.7)

 Right middle lobe-no. (%)

4 (5.3)

 Right lower lobe-no. (%)

14 (18.4)

 Left upper lobe-no. (%)

14 (18.4)

 Left lower lobe-no. (%)

26 (34.2)

 Central

28 (36.8)

 Peripheral

48 (63.2)

Metastatic-no. (%)

2 (2.9)

Lung Primary-no. (%)

68 (97.1)

Histology

 

 Adenocarcinoma

40 (57.1)

 Squamous

17 (24.3)

 NSCLC-NOS

11 (15.7)

Tumor Size-median (range)

2.3 (0.6–5.5) cm

 ≤3 cm

53 (69.7)

 >3 cm

23 (30.3)

Median GTV (range)

6.6 (0.3–150.4) cc

Median PTV (range)

20.8 (12.4–308.2) cc

Median total dose (range)

50 (25–60) Gy

 1 fraction (%)

19 (27.1 %)

 3–8 fractions (%)

51 (72.9 %)

  1. Abbreviations: NSCLC non-small-cell lung cancer, NOS Not otherwise specified, GTV gross tumor volume, PTV planning target volume